IL-23 promotes PD-L1 expression and tumor immune evasion via METTL16 pathway.
It is elucidated that IL-23 upregulates METTL16, which in turn enhances PD-L1 expression and facilitates tumor immune escape, which establishes the IL-23/METTL16/PD-L1 axis as a novel regulatory pathway and potential therapeutic target in cancer immunotherapy.